ANI Pharmaceuticals Stock Forecast, Price & News

ANI Pharmaceuticals (NASDAQ:ANIP) Frequently Asked Questions

Is ANI Pharmaceuticals a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ANI Pharmaceuticals stock.
View analyst ratings for ANI Pharmaceuticals or view top-rated stocks.

How has ANI Pharmaceuticals' stock been impacted by COVID-19?

ANI Pharmaceuticals' stock was trading at $38.30 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ANIP shares have increased by 6.4% and is now trading at $40.77.
View which stocks have been most impacted by COVID-19.

Are investors shorting ANI Pharmaceuticals?

ANI Pharmaceuticals saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 233,600 shares, a decline of 53.1% from the October 31st total of 497,700 shares. Based on an average daily volume of 183,700 shares, the short-interest ratio is currently 1.3 days. Approximately 2.1% of the shares of the company are short sold.
View ANI Pharmaceuticals' Short Interest.

When is ANI Pharmaceuticals' next earnings date?

ANI Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 8th 2022.
View our earnings forecast for ANI Pharmaceuticals.

How were ANI Pharmaceuticals' earnings last quarter?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) issued its quarterly earnings results on Sunday, October, 31st. The specialty pharmaceutical company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.70 by $0.31. ANI Pharmaceuticals had a negative net margin of 10.40% and a positive trailing twelve-month return on equity of 17.80%. During the same quarter last year, the business posted $0.70 EPS.
View ANI Pharmaceuticals' earnings history.

What price target have analysts set for ANIP?

3 equities research analysts have issued 12 month target prices for ANI Pharmaceuticals' stock. Their forecasts range from $65.00 to $70.00. On average, they expect ANI Pharmaceuticals' share price to reach $68.33 in the next twelve months. This suggests a possible upside of 67.6% from the stock's current price.
View analysts' price targets for ANI Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are ANI Pharmaceuticals' key executives?

ANI Pharmaceuticals' management team includes the following people:

• Nikhil Lalwani, President, Chief Executive Officer & Director
• James G. Marken, Senior VP-Operations & Product Development
• Stephen P. Carey, Chief Financial Officer, Secretary & VP
• Rob W. Schrepfer, SVP-New Business Development & Specialty Sales
• Christopher K. Mutz, Chief Commercial Officer & Head-Rare Diseases

What is Arthur Przbyl's approval rating as ANI Pharmaceuticals' CEO?

1 employees have rated ANI Pharmaceuticals CEO Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among ANI Pharmaceuticals' employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of ANI Pharmaceuticals' key competitors?

Some companies that are related to ANI Pharmaceuticals include Xencor (XNCR), Nektar Therapeutics (NKTR), Taro Pharmaceutical Industries (TARO), Agios Pharmaceuticals (AGIO), Dynavax Technologies (DVAX), Turning Point Therapeutics (TPTX), Trillium Therapeutics (TRIL), Avid Bioservices (CDMO), Global Blood Therapeutics (GBT), Erasca (ERAS), Enanta Pharmaceuticals (ENTA), Ironwood Pharmaceuticals (IRWD), Morphic (MORF), Atai Life Sciences (ATAI) and Myovant Sciences (MYOV).
View all of ANIP's competitors.

What other stocks do shareholders of ANI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC).

What is ANI Pharmaceuticals' stock symbol?

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

Who are ANI Pharmaceuticals' major shareholders?

ANI Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (11.86%), Thompson Siegel & Walmsley LLC (3.53%), Dimensional Fund Advisors LP (2.97%), William Blair Investment Management LLC (2.93%), Goldman Sachs Group Inc. (2.44%) and Deutsche Bank AG (1.51%). Company insiders that own ANI Pharmaceuticals stock include Patrick D Walsh and Thomas Haughey.
View institutional ownership trends for ANI Pharmaceuticals.

Which major investors are selling ANI Pharmaceuticals stock?

ANIP stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Goldman Sachs Group Inc., BlackRock Inc., Public Sector Pension Investment Board, Assenagon Asset Management S.A., Two Sigma Investments LP, Geode Capital Management LLC, and Two Sigma Advisers LP.
View insider buying and selling activity for ANI Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying ANI Pharmaceuticals stock?

ANIP stock was bought by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Marathon Capital Management, Thompson Siegel & Walmsley LLC, Deutsche Bank AG, Altium Capital Management LP, Parkman Healthcare Partners LLC, Mitsubishi UFJ Asset Management UK Ltd., and SG Americas Securities LLC. Company insiders that have bought ANI Pharmaceuticals stock in the last two years include Patrick D Walsh, and Thomas Haughey.
View insider buying and selling activity for ANI Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of ANI Pharmaceuticals?

Shares of ANIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ANI Pharmaceuticals' stock price today?

One share of ANIP stock can currently be purchased for approximately $40.77.

How much money does ANI Pharmaceuticals make?

ANI Pharmaceuticals has a market capitalization of $519.90 million and generates $208.48 million in revenue each year. The specialty pharmaceutical company earns $-22.55 million in net income (profit) each year or ($1.83) on an earnings per share basis.

How many employees does ANI Pharmaceuticals have?

ANI Pharmaceuticals employs 369 workers across the globe.

What is ANI Pharmaceuticals' official website?

The official website for ANI Pharmaceuticals is www.anipharmaceuticals.com.

Where are ANI Pharmaceuticals' headquarters?

ANI Pharmaceuticals is headquartered at 210 Main Street West, Baudette MN, 56623.

How can I contact ANI Pharmaceuticals?

ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company can be reached via phone at (218) 634-3500, via email at [email protected], or via fax at 218-634-3540.